Physician profile
Andrew Hwang
NPI 1154858694
$6,356.29
in general payments reported to CMS, 2019-2025
46 companies · $1,615 in 2025
The $1,615 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $601 · 2022: $1,827 · 2023: $1,044 · 2024: $1,269 · 2025: $1,615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,861 · Education: $67.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,861.49 |
| Education | $67.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $589.04 | 2022-2025 | Tecvayli, Erleada, Balversa |
| Alexion Pharmaceuticals, INC. | $405.22 | 2021-2022 | |
| Lilly USA, LLC | $396.44 | 2021-2025 | Verzenio, Jaypirca |
| Gilead Sciences, INC. | $367.99 | 2022-2025 | Trodelvy |
| Genzyme Corporation | $331.44 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $290.91 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $232.74 | 2022-2025 | Darzalex, Tecvayli, Carvykti |
| Takeda Pharmaceuticals U.S.A., INC. | $225.32 | 2022-2023 | Iclusig |
| Astrazeneca Pharmaceuticals LP | $214.24 | 2023-2025 | Imfinzi, Tagrisso, Lynparza |
| Amgen INC. | $214.04 | 2022-2025 | Lumakras, Imdelltra (Amg757), Blincyto |
| Jazz Pharmaceuticals INC. | $213.86 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $188.04 | 2024-2025 | Reblozyl, Opdivo |
| Genentech USA, INC. | $178.77 | 2023-2025 | Tecentriq, Polivy |
| Incyte Corporation | $178.71 | 2022-2025 | Jakafi, Monjuvi, Zynyz |
| Blueprint Medicines Corporation | $170.10 | 2023-2025 | Ayvakit |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $152.15 | 2024-2025 | |
| Astellas Pharma US INC | $150.66 | 2022-2024 | Xospata |
| Beone Medicines USA, INC. | $136.57 | 2025 | Brukinsa, Tevimbra |
| Daiichi Sankyo INC. | $129.89 | 2023-2025 | Enhertu, Datroway, Injectafer |
| Pharmacosmos Therapeutics INC. | $129.50 | 2022-2024 | Cosela |
| Eisai INC. | $113.76 | 2022 | |
| Emd Serono, INC. | $107.07 | 2023-2024 | Tepmetko |
| Karyopharm Therapeutics INC. | $103.55 | 2024-2025 | Xpovio |
| Adc Therapeutics America, INC. | $99.39 | 2022 | |
| Springworks Therapeutics, INC. | $95.86 | 2024-2025 | Ogsiveo |
| Rigel Pharmaceuticals, INC. | $83.72 | 2022 | |
| Agios Pharmaceuticals, INC. | $83.02 | 2024-2025 | Pyrukynd |
| Celgene Corporation | $81.64 | 2024-2025 | Reblozyl |
| Exelixis INC. | $69.08 | 2024-2025 | Cabometyx |
| Glaxosmithkline, LLC. | $67.00 | 2025 | |
| Regeneron Pharmaceuticals, INC. | $59.00 | 2025 | Libtayo |
| Merck Sharp & Dohme LLC | $56.70 | 2023-2025 | Keytruda, Keytruda Qlex |
| Deciphera Pharmaceuticals INC. | $54.40 | 2024-2025 | Qinlock, Romvimza |
| Taiho Oncology, INC. | $53.24 | 2024-2025 | |
| Genentech, INC. | $44.35 | 2024 | Itovebi |
| Pfizer INC. | $32.23 | 2025 | |
| Syndax Pharmaceuticals, INC. | $31.71 | 2025 | |
| Pharmaessentia USA Corporation | $30.76 | 2025 | Besremi |
| Tersera Therapeutics LLC | $30.00 | 2023 | Xermelo |
| X4 Pharmaceuticals, INC. | $28.10 | 2024 | Xolremdi |
| Coherus Oncology, INC. | $27.04 | 2025 | Loqtorzi |
| Bayer Healthcare Pharmaceuticals INC. | $24.49 | 2023 | |
| Seagen INC. | $24.30 | 2023 | Adcetris |
| Morphosys, US INC. | $22.23 | 2023 | Monjuvi |
| Kyowa Kirin, INC. | $20.52 | 2025 | |
| Servier Pharmaceuticals LLC | $17.50 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Hwang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.